Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1301-1320 of 2,251 trials

Anticoagulant Treatments for Intra-Cardiac Thrombus: The ARGONAUT Trial

We are comparing a new direct oral anticoagulant with a standard vitamin K antagonist in patients with intra-cardiac thrombus. The goal is to see which treatment better reduces complications and promotes thrombus regression.

Intracardiac Thrombus>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

BCR-ABL1+ Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Relapsing Multiple Sclerosis: YTB323 Treatment Study

We are testing a new treatment called YTB323 for people with Relapsing Multiple Sclerosis who have had ongoing disease activity despite previous therapies. The study aims to assess its safety and effects on disease progression.

Relapsing Multiple Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurology

INZ-701 for ENPP1 and ABCC6 Deficiency

We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyGeneralized Arterial Calcification of InfancyEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Colon Cancer: HIPEC with Mitomycin-C Study

We are investigating whether adding a special chemotherapy during surgery helps prevent cancer recurrence in patients with colon cancer that has spread to the abdomen. This study compares outcomes for those receiving this treatment versus standard care.

Peritoneal Metastases of Colorectal Cancer>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOncology

Pain Relief for First-Degree Perineal Tears: Emla Cream vs. Injection

We are comparing a topical cream to an injection for pain relief in women with first-degree perineal tears after childbirth. The goal is to see which method provides better comfort during and after the repair.

First-Degree Perineal Laceration6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Pemigatinib for Solid Tumors with FGFR Alterations

We are studying whether pemigatinib can help patients with recurrent or metastatic solid tumors that have a specific gene change. The trial aims to assess its effects on tumor growth and overall patient health.

Recurrent or Metastatic Solid Cancer with FGFR Alterations>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Pancreatic Cancer: CEB-01 Treatment Study

We are exploring a new treatment called CEB-01 for people with pancreatic cancer to see how safe it is and if it may help improve their condition.

Pancreatic Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Migraine Treatment: Rimegepant for Kids and Teens

We are studying the safety of rimegepant for treating migraines in children and adolescents aged 6 to under 18. This trial will help us understand how well the medication works and if there are any side effects.

Migraine1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Septic Shock: Landiolol Infusion Study

We are investigating whether Landiolol can improve blood flow and heart function in patients with septic shock. This study compares its effects to standard treatments for managing rapid heart rates.

Microcirculatory Abnormalities in Septic Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Tuberculosis Treatment: Tedizolid vs. Linezolide

We are studying how well tedizolid works compared to linezolide in reducing tuberculosis bacteria in patients. This trial aims to find out which treatment may be more effective in the first days of therapy.

Multidrug-Resistant TuberculosisEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Pancreatic Exocrine Insufficiency: Creon® Therapy

We are studying how well Creon® helps patients with pancreatic exocrine insufficiency after surgery. The goal is to see if it improves symptoms and nutritional health.

Pancreatic Exocrine Insufficiency6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

Squamous Cell Carcinoma of the Penis: Lymphadenectomy and Chemotherapy Study

We are studying a treatment combining surgery and chemotherapy for patients with inguinal lymph node metastases. The goal is to see if this approach improves survival and reduces the chance of cancer returning.

Penis Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Treatment: Cangrelor and Bivalirudin

We are studying a new combination of medications for patients with heart attacks in critical condition. The goal is to see if this treatment can prevent blood clots while keeping bleeding risks low.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Lutetium Lu 177 Edotreotide for Pediatric Tumors

We are studying a new targeted therapy for children with somatostatin receptor-positive tumors to find the right dose and evaluate its safety. This trial will also look at how well the treatment works compared to standard care.

RhabdomyosarcomaLymphomaNeuroendocrine Tumor>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyPediatrics

Diffuse Large B-Cell Lymphoma: Axicabtagene Ciloleucel Study

We are studying a new treatment for patients with late relapse of diffuse large B-cell lymphoma to see if it improves their condition and quality of life. The trial also looks at the safety of this treatment.

Recurrent B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Vaginal Progesterone for IVF: Improving Live Birth Rates

We are studying whether vaginal progesterone helps women achieve live births after frozen embryo transfer. The trial compares outcomes between those receiving progesterone and those who do not.

Infertility≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Prostate Cancer Diagnosis: 18F-PSMA PET/MRI Study

We are testing a new imaging method to see how well it identifies clinically significant prostate cancer. This may help improve diagnosis accuracy for patients.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyUrology